ArticleJournal of nanobiotechnology2025
Targeting JAK2 with a multifunctional nanoinhibitor for long-lasting anti-inflammatory effects and bone repair.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- IGFBP5 alleviates periodontitis by reversing human dental follicle stem cell senescence via the non-canonical Wnt pathway.International journal of oral science · 2026Article
- Palmitic Acid Induces Inflammatory Environment and Is Involved in Pyroptosis in a Human Dental Pulp Cell Line.Dentistry journal · 2026Article
- Near-infrared light-activated lidocaine microneedle patch for rapid local anesthesia.Theranostics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Dysregulation of the JAK2/STAT3 pathway disrupts immune balance and tissue homeostasis, leading to persistent inflammation and subsequent bone loss. Yet, commonly used JAK2 inhibitors with hydrophobicity primarily suppress inflammation but often fail to provide sustained pharmacological effects and address ongoing inflammation-induced bone destruction. Here, using computer-aided drug design, we developed hydrophilic calcium-doped carbon dots (Ca-CDs) as a multifunctional nanoinhibitor targeting JAK2. The Ca-CDs can block the excessive activation of the JAK2/STAT3 pathway by binding to JAK2, thereby reducing the secretion of pro-inflammatory cytokines and exerting anti-inflammatory effects. Furthermore, the Ca-CDs promote bone regeneration under inflammatory conditions and serve as crosslinking junctions that facilitate the formation of a Ca-CDs-based alginate hydrogel, thereby enabling prolonged drug retention and controlled release. Their application in the representative inflammatory microenvironment of periodontitis successfully validated the efficacy of the Ca-CDs-based therapeutic strategy. Overall, targeting JAK2 with Ca-CDs nanoinhibitor offers a promising treatment option for JAK2-associated inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.